Expert Video - What are the goals of mutation-driven MDS treatments?
Prof. Valeria Santini, an expert on MDS from the University of Florence, explains that mutation-driven treatments aim to affect MDS progression by targeting chromosomal alterations or gene mutations present in MDS. She also describes how the presence of additional mutations can affect the goal of slowing progression.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.